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Time-Dependent Cytotoxic Properties of Terpyridine-Based 
Copper Complexes 
Jordi Grau,[a] Amparo Caubet,*[a] Olivier Roubeau,[b] David Montpeyó,[c] Julia Lorenzo[c] and Patrick 
Gamez*[a,d,e] 
 
Abstract: Five copper complexes supported by terpyridine ligands 
were prepared and characterized, viz. [Cu3Cl4(Naphtpy)2][CuCl2] (1), 
[Cu2Cl2(Naphtpy)2](ClO4)2 (2), [CuCl2(Naphtpy)]2(MeOH)3(H2O) (3), 
[CuCl2(Cltpy)] (4) and [Cu(Cltpy)2](ClO4)2 (5); (where Naphtpy 
stands for 4’-((naphthalen-2-yl)methoxy)-2,2′:6′,2′′-terpyridine and 
Cltpy for 4′-chloro-2,2′:6′,2′′-terpyridine). Their DNA-interaction 
abilities were investigated, and their cytotoxic behaviors were 
examined with three cells lines, namely with human ovarian 
carcinoma cells (A2780) and its derived cisplatin-resistant line 
(A2780cis), and human cervix adenocarcinoma cells (HeLa). All 
compounds show good cytotoxic properties (especially after 72 h 
incubation). Remarkably, two compounds, i.e. 4 and 5, are almost 
inactive after 24 h (particularly 4), but are highly active after 72 h, 
with IC50 values in the low micromolar to submicromolar range. 
Compounds 1 and 2 induce necrosis, whereas late apoptosis is 
observed with 3−5, 4 exhibiting a behaviour close to that of cisplatin. 
Introduction 
Nucleases are enzymes capable of cleaving DNA by rapidly 
hydrolyzing its phosphodiester bond.[1, 2] These biological 
catalysts are involved in a variety of biological functions, 
including DNA replication, recombination, repair, regulation, 
processing and degradation.[2, 3] Over the last three decades, 
research efforts have been dedicated to the design of small 
coordination compounds that mimic nuclease activity.[4] Such 
hydrolytically-cleaving metallonucleases have been used to 
substitute restriction enzymes or footprinting agents, and as 
simple models to elucidate the mechanism of action of the 
natural enzymes.[3, 5] 
When the coordination compounds contain redox-active 
metal ions, the oxidative cleavage of DNA may occur.[6] For 
example, the binding of iron to the glycopeptide bleomycin 
generates a complex with anticancer properties,[7] which are 
attributed to its ability to cleave DNA oxidatively.[8] Hence, a 
great number of artificial metallonucleases (AMNs) have been 
described in the literature for their potential use as anticancer 
agents.[3, 9] From the different transition metals used, copper 
appears to be one of the most attractive; indeed, it is an 
essential trace element and may therefore be less toxic to 
normal cells and thus lead to less harmful side effects.[10] The 
first copper-based AMN, a copper-phenanthroline complex was 
reported at the end of the 1970’s;[11] since then, a great number 
of copper complexes were developed with interesting DNA-
cleaving properties.[10, 12] Actually, two copper-based compounds 
(with 2,2’-bipyridine and 1,10-phenanthroline as N-donor 
ligands) from the Casiopeínas® family are currently in clinical 
trials.[13] 
 Some years ago, we have described three copper-
terpyridine nitrato complexes with interesting cytotoxic 
properties.[14] In this previous study, the effect of supramolecular 
interactions on the biological properties was investigated, and 
the complex [Cu(naphtpy)(NO3)(H2O)](NO3)(MeOH) (where 
naphtpy stands for 4’-((naphthalen-2-yl)methoxy)-2,2′:6′,2′′-
terpyridine; Figure 1) exhibited notable cell toxicity behavior 
against several cancer cell lines.[14] In the present study, the 
ligand naphtpy was used to prepare copper(II) complexes with 
CuCl2 and Cu(ClO4)2 as the metal sources (instead of Cu(NO3)2). 
For comparison purposes, copper complexes obtained by the 
reaction of 4′-chloro-2,2′:6′,2′′-terpyridine (Cltpy; Figure 1) and 
CuCl2 or Cu(ClO4)2 were synthesized as well. Hence, five copper 
compounds were obtained and characterized, and their 
interaction with DNA was subsequently examined. Lastly, their 
respective cytotoxicity against ovarian carcinoma cells (A2780), 
their cisplatin-resistant line (i.e. A2780cis) and human cervix 
adenocarcinoma cells (HeLa) was evaluated, which provided 
interesting data. Cell-cycle studies with HeLa cells were also 
carried out with the five complexes, comparing their behavior 
with that of cisplatin. 
Results and Discussion 
Preparation of the copper complexes 
 
Reaction of Naphtpy with 1.5 equiv. of CuCl2·2H2O in methanol 
at 40 ºC produces the mixed-valence CuICuII compound 
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[Cu3Cl4(Naphtpy)2][CuCl2] (1). 1 crystallizes in the triclinic space 
group P1̅ (see Table S1). Selected bond distances and angles 
are listed in Table S2. 
 
Figure 1. Representations of the ligands 4’-chloro-2,2’:6’,2’’-terpyridine (Cltpy) 
and 4’-((naphthalen-2-yl)methoxy)-2,2’:6’,2’’-terpyridine(Naphtpy). 
A representation of the solid-state structure of 1 is shown in 
Figure 2. The cationic part of 1, namely [{CuCl(Naphtpy)}2(μ-
CuCl2)]+, is formed by two square-pyramidal 
[{CuCl(Naphtpy)}2(μ-CuCl2)]+ units linked by a [CuCl2]‒ unit. The 
anionic part of 1 is a linear [Cl−CuI−Cl]−, which has been 
observed in structures described in the literature.[15] Hence, 
tetracopper compound 1 contains two copper(II) and two 
copper(I) ions. Since, the source of metal was copper(II) 
dichloride, the structure of 1 thus indicates that part of divalent 
copper was reduced during the synthesis. Actually, a number of 
copper-terpyridine complexes have been reported as catalysts 
for the oxidation of alcohols,[16] and even a mixed-valence 
CuICuII compound was described, which was obtained by partial 
reduction of copper(II) in the presence of TEMPO (viz. 2,2,6,6-
tetramethylpiperidinyl-1-oxyl).[17] It can be pointed out here that 
this tendency of Cu/tpy complexes to undergo redox reactions is 
of great importance regarding their potential ability to oxidatively 
cleave DNA. In fact, it has been shown that copper-terpyridine 
complexes acting as good oxidation catalysts were also efficient 
DNA cleavers.[18] In the present case, it appears that the solvent 
of the reaction, namely methanol, is the reducing agent 
converting copper(II) into copper(I) ions. Thus, methanol is 
probably oxidised to methanal (and eventually to formic acid). 
Reaction of Naphtpy with 1.5 equiv. of Cu(ClO4)2·6H2O in 
methanol at 40 ºC yields the dinuclear compound 
[Cu2Cl2(Naphtpy)2](ClO4)2 (2), whose crystal structure is 
depicted in Figure 2. As 1, 2 crystallizes in the triclinic space 
group P1̅ (see Table S1). Selected bond distances and angles 
are listed in Table S3. The solid-state structure of 2, depicted in 
Figure 2, reveals that the dinuclear complex consists of a 
cationic [{CuCl(Naphtpy)}2(μ-Cl)2]2+ unit balanced by two 
perchlorate anions. The symmetry-related metal centres are in a 
square-pyramidal environment formed by a tridentate, N,N,N-
Naphtpy ligand and a chloride in the square plane, a second 
chloride occupying the axial position (as observed for the 
copper(II) centres in 1). The copper(II) ions are doubly bridged 
by chloride anions, and are separated by a distance of 3.5004(5) 
Å. The coordination bond distances and angles (see Table S3) 
are in normal ranges for such copper complexes.[19] Remarkably, 
2 contains chloride ions whereas these anions were not added 
during the synthesis (see Experimental Section). Therefore, the 
chlorides are generated during the formation of 2, most likely 
from the perchlorates. In effect, such chemical transformation of 
perchlorate to chloride has already been observed.[20] 
 
Figure 2. Representations of the molecular structures of 
[Cu3Cl4(Naphtpy)2][CuCl2] (1), [Cu2Cl2(Naphtpy)2](ClO4)2 (2), 
[CuCl2(Naphtpy)]2(MeOH)3(H2O) (3) and [CuCl2(Cltpy)] (4). H atoms (except 
for solvent molecules) are not shown for clarity. 
It can be stressed here that ClO4− is commonly resistant to 
reduction although it is a strong oxidizing agent under acidic 





 + 8 H
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 = 1.389 V     (1) 
 
Thus, the fact that ClO4− was chemically transformed to Cl- in 
the presence of Cu-Naphtpy species again illustrates their 
interesting redox properties (see compound 1 above), which can 
be important for their DNA-cleaving abilities. It can also be 
pointed out that perchlorate is an environmental contaminant;[22] 
Hence, such Naphtpy-containing copper complex may be 
applied to decontaminate ground water. 
Reaction of Naphtpy with 1 equiv. of CuCl2·2H2O in 
methanol at 40 ºC produces the mononuclear compound 
[CuCl2(Naphtpy)]2(MeOH)3(H2O) (3). 3 crystallizes in the 
monoclinic space group P21/n (see Table S4). Selected bond 
distances and angles are listed in Table S5. The crystal 
structure of 3 is shown in Figure 2. The copper(II) ion is in a 
square-pyramidal environment formed by a terpyridine unit and 
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completing the coordination geometry at the axial position. The 
coordination bond distances and angles (see Table S5) are 
comparable with those reported in the literature for this 
compound.[23] 
Reaction of Cltpy with 1 equiv. of CuCl2·2H2O in methanol at 
40 ºC produces the mononuclear copper compound 
[CuCl2(Cltpy)] (4), which crystallizes in the monoclinic space 
group P21/c (Table S4). Selected bond distances and angles are 
listed in Table S6. The crystal structure of 4, depicted in Figure 2, 
shows that the metal centre is in a square-pyramidal 
environment similar to that of compound 3 (see above and 
Figure 2). The coordination bond distances and angles (Table 
S6) are comparable with those observed for the structure 
already reported for this complex.[17] 
Reaction of Cltpy with 1 equiv. of Cu(ClO4)2·6H2O in 
methanol at 40 ºC yields the mononuclear copper compound 
[Cu(Cltpy)2](ClO4)2 (5); the crystal structure of 5 could not be 
determined but its elemental analysis suggests that it is the bis- 
Cltpy copper(II) complex depicted in Figure 3. Actually, the X-
ray structure of this compound was reported.[24] 
 
Figure 3. Proposed structure for compound 5. 
Interaction with DNA 
 
The interaction of compounds 1−5 with DNA was subsequently 
investigated. First, gel electrophoretic studies were carried out 
with plasmid DNA. Structural changes induced by the interaction 
of the different copper complexes with the biomolecule can be 
visualized by the distinct electrophoretic mobilities of the 
consequent, various forms of DNA, namely Form I (supercoiled 
DNA), Form II (nicked DNA) and Form III (linear DNA). A 
reducing agent was used, namely ascorbic acid (1 mM), was 
used to simulate the reducing environment found in cells. A 
reference copper-based chemical nuclease, i.e. a bis-1,10-
phenanthroline-copper species ([Cu(Phen)]2+),[1] was used. The 
electrophoresis results achieved are shown in Figure 4. 
 Multinuclear compound 1 drastically affects the 
electrophoretic mobility of DNA. Indeed, at a concentration of 20 
μM, Form I is converted into Form II (lane 6). Upon further 
increase of the concentration of 1, the biomolecule is completely 
damaged (lanes 7−10). Dinuclear compound 2 appears not to be 
harmful to the double helix (Figure 4); at all complex 
concentrations (lanes 4−10), the bands corresponding to Form I 
and Form II are not modified in the presence of 2 (even at high 
concentrations), in contrast to the reference compound 
[Cu(Phen)]2+ (lanes 2 and 3). Mononuclear compound 3 is more 
active than 2, but much less damaging than 1; some alteration of 
the DNA structure/conformation is only seen from a 
concentration of 80 μM (lanes 9 and 10). 
 
Figure 4. Agarose gel electrophoresis images of pBR322 plasmid DNA (15 
μM b.p.) incubated for 1 h at 37 °C in cacodylate-NaCl buffer (pH 7.2) with 
increasing concentrations of compounds 1−5, in the presence of a reducing 
agent, namely ascorbic acid (1 mM). For each compound (see corresponding 
image), lane 1: pure plasmid DNA; lane 2: [Cu(Phen)]2+ = 5 μM (reference 
compound); lane 3: [Cu(Phen)]2+= 100 μM; lane 4: [compound] = 5 μM; lane 5: 
[compound] = 10 μM; lane 6: [compound] = 20 μM; lane 7: [compound] = 40 
μM; lane 8: [compound] = 60 μM; lane 9: [compound] = 80 μM; lane 10: 
[compound] = 100 μM. 
Compound 4 is capable of efficiently cleaving DNA at a 
concentration of 20 μM, for which Form I is totally converted to 
mostly Form II and to some Form III (lane 6). At concentrations  
40 μM, the DNA appears to be degraded into single-stranded 
pieces (lanes 7−10). Complex 5 is even more efficient since 
already a 10 μM solution of this compound produces a 
significant amount of Form II (lane 5). As for 4, at concentrations 
 40 μM, 5 significantly damages the DNA (lanes 7−10).  
In summary, the Cltpy-containing complexes 4 and 5 are 
comparatively more efficient DNA cleavers than the Naphtpy-
based ones; only the mixed-valence complex 1 exhibits a similar 
cleaving activity to those of 4 and 5. It can finally be pointed out 
that without ascorbic acid, the plasmid DNA is not affected 
(Figure S1); hence, the reducing agent is required to observe 
the (oxidative) cleaving activity of the complexes. 
 
Competitive binding studies using intercalating ethidium 
bromide (EB) bound to calf thymus DNA (ct-DNA) were 
subsequently carried out. Hence, the potential displacement of 
EB by compounds 1−5 was followed by fluorescence 
spectroscopy (EB being strongly fluorescent when intercalated 
between DNA base pairs). Fluorescence spectra were thus 
recorded at constant concentrations of EB and ct-DNA, viz. 25 
μM, by adding increasing quantities of the copper compounds; 
the range of concentrations used was 5−25 μM. The resulting 














This article is protected by copyright. All rights reserved.
FULL PAPER    





representative example. The corresponding spectra for 2−5 are 
shown in Figure S2. It can be pointed out that all the complexes 
do not induce a significant release of EB, and that the Naphtpy-
containing 1−3 are comparatively better fluorescence quenchers 
than Cltpy-containing 4 and 5. This may be explained by the 
naphthyl group of the Naphtpy ligand, which may intercalate 
between base pairs and therefore expel some EB; actually, the 
same tendency was observed in a previous study with this family 
of ligands.[14] 
 
Figure 5. Emission spectra of the DNA-EB complex (25 μM), λexc = 514 nm, 
λem = 610 nm, upon addition of increasing amounts of complex 1 (5–25 μM). 
The blue arrow shows the diminution of the emission intensity with the 
increase in concentration of 1. 
The relative affinity of complexes 1–5 towards ct-DNA was 
evaluated by determining their Stern–Volmer constant KSV 




= 1 + 𝐾𝑆𝑉[𝑐𝑜𝑚𝑝𝑙𝑒𝑥] (2) 
 
In equation (2), I0 is the initial fluorescence intensity of EB 
bound to ct-DNA and I is the fluorescence intensity when adding 
increasing amounts of complex, in the range 5−25 μM. The KSV 
constants achieved are listed in Table 1. 
The KSV values obtained are between 0.90 and 6.94 103 M−1, 
well below the magnitude expected for classical intercalators, 
which is in the range 106 M−1 (viz. three orders of magnitude 
superior to that observed for 1−5).[25] The KSV values for 1−5 are 
in fact consistent with an external DNA-binding mode.[26] Such 
weak interactions with DNA were already suggested by the gel 
electrophoresis studies without reducing agent, which revealed 
that 1−5 were no able to significantly alter the 
structure/conformation of the double helix (see Figure S2). 
 
Table 1. Stern–Volmer constants KSV determined for 1–5 competing with 
DNA-bound EB[a] 
Complex KSV (103 M−1)[b] Log KSV 
1 6.94 ± 0.10 3.84 
2 2.49 ± 0.32 3.40 
3 5.96 ± 0.94 3.78 
4 0.90 ± 0.13 2.95 
5 1.21 ± 0.30 3.08 
[a] KSV is determined from the slope of the linear Stern–Volmer plot, i.e. I0/I 
versus [complex], obtained using λem = 610 nm. [b] The results shown are 
means ± SD of at least three experiments. 
 
 The binding of compounds 1−5 to DNA was then 
investigated by UV-Vis spectroscopy.[27] Absorption spectra were 
recorded for 25 μM solutions of each complex to which were 
added increasing amounts of ct-DNA (from 1 to 25 μM). The 
corresponding spectra (range 190-400 nm) for 1, which are 
representative for all the other compounds (viz. 2−5), are shown 
in Figure S3.  
 
Figure 6. Absorption spectra (in the range 300-360 nm) of a 25 μM solution of 
1 upon addition of increasing amounts of ct-DNA (1–25 μM). The MLCT band 
at λ = 316 nm was used to determine Kb. The red arrow shows the decrease in 
absorption intensity with increasing [ct-DNA]. 
Absorption bands in the range 300−360 nm, corresponding 
to metal-to-ligand charge transfer (MLCT), were used to 
examine the interaction of 1−5 with ct-DNA (Figures 6 and S4). 
For 1, a decrease of the absorption band at λ = 316 nm is 
observed when increasing the concentration of ct-DNA (Figure 
6). No red shifts of the absorption bands take place, therefore 
indicating that 1 is not intercalating between base pairs,[28] as 
already suggested by the fluorescence studies (see above); in 
fact, it appears that 1 interacts electrostatically with the 
biomolecule.[29, 30] The intrinsic binding constant characterizing 

























This article is protected by copyright. All rights reserved.
FULL PAPER    





In equation (3), [DNA] represents the concentration of ct-
DNA in base pairs, εa is the extinction coefficient at the given [ct-
DNA], εf is the extinction coefficient of the free complex in 
solution (determined from Aobs/[complex]), and ε0 is the 
extinction coefficient for the fully bound compound. The Kb 
values for 1−5 were thus determined, which are listed in Table 1. 
 
Table 2. Intrinsic binding constants Kb determined for 1–5 interacting with 
ct-DNA[a] 
Complex Kb (106 M−1)[b] Log Kb 
1 3.41 ± 0.79 6.53 
2 0.22 ± 0.06 5.34 
3 1.05 ± 0.02 6.02 
4 1.96 ± 0.64 6.29 
5 0.71 ± 0.05 5.85 
[a] The Kb values are determined from the ratio of the slope to the intercept 
of the corresponding linear [DNA]/(εa − εf) vs. [DNA] plots, which are 
obtained for [complex] : [DNA] ratios ≤ 1:1 (λ = 316 nm (1), λ = 312 nm (2), 
λ = 315 nm (3), λ = 337 nm (4), λ = 322 nm (5)). [b] The results shown are 
means ± SD of at least three experiments. 
 
 A Kb value of 3.41 ± 0.79 106 M−1 is obtained for 1 (Table 
1), illustrating a strong interaction of this compound with the 
double helix. Compounds 2−4 exhibit similar features (Figure S4 
and Table 1), namely hypochromism without red shifting is 
observed, indicating that they are most likely acting as “outside 
binders”.[30] Though, the interactions are weaker than that of 1, 
with 1 >> 4 > 3 >> 2 (see Table 1). 
Compound 5 shows a distinct behaviour; indeed, 
hyperchromism is observed (Figure S4). Both hypochromism 
and hyperchromism suggest structural changes of the DNA 
duplex. Hypochromism may be due to intercalation (if 
accompanied by a red shift) or to electrostatic contacts (as 
probably occurring with 1−4) of the interacting compound.[31, 32] 
Hyperchromism may result from external binding (e.g. surface 
binding),[31, 33] for instance of a cationic species to the negatively 
charged phosphate backbone.[34] Thus, 5 appears to interact at 
the periphery of the DNA double helix. 
Cytotoxicity assays 
 
The cytotoxic properties of 1−5 were assessed using HeLa 
(cervix adenocarcinoma) cells, A2780 (ovarian carcinoma) cells 
and their cisplatin-resistant line A2780cis. IC50 values were 
determined after 24 and 72 hours of incubation at 37 °C. The 
data achieved for 1−5 and those reported for cisplatin are listed 
in Table 3. 
The Naphtpy-containing complexes 1−3 exhibit good 
cytotoxic behaviours, with IC50 values in the submicromolar 
range after 72 h incubation (Table 3). Actually, 1−3 are 5 to 13 
times more active than cisplatin against A2780 cells, and 17 to 
46 more efficient than the platinum drug against A2780cis cells 
and even 42 to 180 times more active than cisplatin against 
HeLa cells. It can even be pointed out that 1 is slightly more 
cytotoxic towards the resistant A2780cis cells after 24 h 
incubation (4.44 vs. 6.09 μM; Table 3). 
 
 
Table 3. IC50 values (μM)[a] for 1−5 and cisplatin against ovarian carcinoma 
(A2780) cells, their cisplatin-resistant line (A2780cis) and cervix 
adenocarcinoma (HeLa) cells, after 24 and 72 h of incubation. 
 24 h 
Compd. A2780 A2780cis HeLa 
1 6.09 ± 0.77 4.44 ± 0.66 7.12 ± 0.44 
2 7.79 ± 1.04 9.27 ± 1.53 7.77 ± 1.32 
3 10.4 ± 1.26 14.0 ± 2.66 14.04 ± 2.94 
4 107 ± 13.2 128 ± 21.3 40.64 ± 23.75 
5 44.1 ± 8.20 61.9 ± 17.18 29.24 ± 16.10 
cisplatin 16.41[b] 74.97[b] 40.25 ± 3.71[d] 
 72 h 
1 0.22 ± 0.02 0.30 ± 0.02 0.08 ± 0.02 
2 0.27 ± 0.03 0.61 ± 0.07 0.13 ± 0.03 
3 0.59 ± 0.05 0.79 ± 0.09 0.35 ± 0.14 
4 0.90 ± 0.19 3.34 ± 0.80 1.44 ± 0.56 
5 3.51 ± 1.43 3.62 ± 0.89 0.59 ± 0.15 
cisplatin 2.8 ± 0.20[c] 13.8 ± 0.20[c] 14.66 ± 2.59[d] 
[a] The IC50 (in μM) shown are mean values ± SE of three independent 
experiments. [b] IC50 values reported by Krieger et al.[35] [c] IC50 values 
reported by Raveendran et al.[36] [d] [b] IC50 values reported by Pilon et 
al.[37] 
 
The activities of Cltpy-based 4 and 5 are even more 
remarkable, particularly that of 4 (Table 3). In fact, while these 
compounds are poorly cytotoxic after 24 h incubation, they 
became significantly more efficient after 72 h incubation (Table 
3). Hence, the activity of 5 is 13 times higher against A2780 cells 
after 72 h incubation, 17 times higher against A2780cis cells and 
50 times against HeLa cells (Table 3). For 4, the incubation-time 
effect is even more drastic; the cytotoxicity goes from 107 to 0.9 
μM (ca. 120 times higher efficiency) with A2780 cells, and from 
128 to 3.34 μM (38 times increased activity) with A2780cis ones 
and from 40.64 to 1.44 μM (28 times more active) against HeLa 
cells. Such variation of the cytotoxic properties of 4 (and of 5) 
may be explained by a modification of the compound in solution 
with time. Therefore, absorption spectra of a solution of 4 were 
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presented in Figure S5 only show the occurrence of a slight 
hyperchromism with time; no wavelength changes nor 
appearance of new bands are observed, thus suggesting that 4 
is rather stable in solution. One possibility would be that the 
chlorine at the 4’-position of the ligand Cltpy is slowly 
hydrolysed, giving rise to the formation of more active (and more 
hydrophilic) species. However, more studies are definitely 
required to elucidate the exact origin of the “delayed” activities 
observed for 4 and 5. 
The resistant factors of A2780cis cells against cisplatin 
towards its parental cell line, range from 4.5 after 24 h to 5 after 
72 h incubation time (Table S7). Complexes 1−5, especially after 
24 h incubation time, show little difference in cytotoxicity against 
A2780 cells and its resistant cell line, the resistant factors 
ranging from 0.7 to 1.4 (Table S7). After 72 h incubation time, 
the complexes also display reduced resistant factors in the 
A2780cis cell line towards the parental cell line, ranging from 1 




 Cells undergoing apoptosis specifically translocate 
phospholipids such as phosphatidylserine (PS) from the inner 
face of the plasma membrane to outside of the cell surface. 
Annexin-V is a phospholipid-binding protein having high affinity 
for phosphophatidylserine; therefore, detection of PS can be 
achieved by staining with Annexin-V followed by flow cytometry 
analysis. Cells are simultaneously stained with propidium iodide 
(PI), which can only enter cells with damaged plasma membrane 
and stains the DNA. Dual staining makes it possible to 
distinguish between early apoptotic cells (Annexin-V+, PI−) and 
late apoptotic (Annexin-V+, PI+) and necrotic/damaged cells 
(Annexin-V−, PI+). The results of Annexin-V/propidium iodide 
(PI) double staining study by flow cytometry are shown in Table 
4. Viable cells are drastically reduced after 24 h of treatment at 
IC50 concentrations with cisplatin and copper complexes. Also, it 
was noticed that the rate of late apoptosis in HeLa cells treated 
with compound 4 was 14.68 %, a value close to that of cisplatin, 
whereas complexes 1, 2, 3 and 5 presented higher values from 
21.5 to 29.5% (Table 4.). Finally, the ratio of early apoptotic cells 
decreased in all treatments with the copper compounds. It is 
also interesting to note that for compounds 1 and 2, the 
percentage of cells in the R4 quadrant that corresponds to 
necrotic or damaged dead cells increased significantly from 
7.94% in the case of cisplatin to 35.47 and 36.09% for 1 and 2, 
respectively. 
 
Table 4. Cell-cycle studies: percentages (%) of HeLa cells in each state 
after treatment with complexes 1−5 and cisplatin at IC50 concentrations for 
24 h. 











Control 86.06 3.65 7.55 2.74 
cisplatin 60.89 15.99 15.18 7.94 
1 30.15 4.82 29.56 35.47 
2 30.81 5.39 27.71 36.09 
3 68.54 7.64 21.55 2.27 
4 79.41 4.37 14.57 1.65 
5 63.27 6.97 24.62 5.13 
 
Conclusions 
Five copper complexes have been prepared from terpyridine-
based ligands with the objective to study their cytotoxic 
properties. The compounds all show interesting cytotoxic 
activities, but their cancer-cell growth inhibitory behaviors 
depend of the nature of the functional group at the 4’ position of 
the terpyridine unit (viz. at the para position of the central 
pyridine ring). If this functional group is a naphthalen-2-yl group, 
i.e. compounds 1−3, the activities observed are elevated after 24 
h incubation with the three cell lines tested, clearly higher than 
that of cisplatin under the same experimental conditions. After 
72 h incubation, IC50 values in the submicromolar range (down 
to 0.08 ± 0.02 μM (that is 80 nM) can even be achieved. 
Remarkably, when position 4’ is occupied by a chlorine atom, 
the resulting copper complexes, namely compounds 4 and 5, 
are almost inactive after 24 h incubation with the different cells, 
but their cytotoxic properties dramatically increase after 72 h of 
incubation. Hence, the IC50 values of 4 and 5 increase by up to 
120 times, after 2 additional days of incubation. Such increase of 
the activity with time may be of interest for practical applications; 
it can indeed be interesting to administer a therapeutic 
compound whose activity is not immediate but is reached after 
some time (prodrug). These evolving behaviors of 4 and 5 may 
be explained by the slow hydrolysis of the 4’-chlorine 
(generating 4'-hydroxy-2,2':6',2''-terpyridine), producing species 
with improved cytotoxicity or/and hydrophilicity. This hypothesis 
will be verified in a subsequent study, whose results will be 
reported in due time. 
Experimental Section 
Materials: all reagents and solvents were obtained from commercial 
sources and used without further purification. [Cu(H2O)(1,10-
phenanthroline)2](NO3)2, the reference copper-based AMN, was prepared 
following a reported procedure.[38] The ligand 4’-((naphthalen-2-
yl)methoxy)-2,2’:6’,2”-terpyridine (Naphtpy) was synthesized as 
described earlier.[14] pBR322 plasmid DNA was purchased from Roche 
and calf thymus DNA was obtained from Sigma-Aldrich. 
Instrumentation and methods: All reactions were performed under 
aerobic conditions. 1H and 13C [39] NMR spectra were recorded at room 
temperature with a Varian Unity 400 MHz spectrometer. Proton and 
carbon chemical shifts are reported in parts per million (ppm, δ scale) and 
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pellets) were recorded in the range 4000–400 cm−1 using a Nicolet-5700 
FT-IR, and data are represented as the frequency of absorption (cm−1). 
UV-Vis experiments were done with a Varian Cary-100 
spectrophotometer and the fluorescence measurements were performed 
with a KONTRON SFM 25 spectrofluorometer. Elemental analyses and 
ESI mass spectroscopy were performed by the Servei de Microanalisi, 
Serveis Cientificotècnics of the University of Barcelona. For the ESI MS, 
an LC/MSD-TOF Spectrometer from Agilent Technologies, equipped with 
an electrospray ionization (ESI) source was used. 
Preparation of the copper(II) complexes 
Compound 1: 0.195 mmol (76 mg) of Naphtpy was dissolved in 15 mL 
of warm methanol at 40 ºC. This solution was subsequently added to a 
warm methanolic solution (10 mL) of CuCl2·2H2O (0.293 mmol; 50 mg). 
The resulting reaction mixture was stirred at 40 ºC for 4 hours. After 
filtration, the blue solution obtained was left unperturbed for the slow 
evaporation of the solvent. Dark-green single crystals of 1, suitable for X-
ray diffraction measurements, were obtained with a yield of 71% (86 mg; 
based on Naphtpy). Elemental analyses calcd. for C52H38Cl6Cu4N6O2: C, 
50.13; H, 3.07; N, 6.75. Found: C, 50.02; H, 3.25; N, 6.57. IR (KBr pellet): 
?̅? = 3412, 3278, 3031, 2936, 1613, 1571, 1476, 1407, 1225, 1037, 1021, 
822, 792 cm−1. 
Compound 2: 0.185 mmol (72 mg) of Naphtpy was dissolved in 15 mL 
of warm methanol at 40 ºC. Next, this solution was added to a warm 
methanolic solution of Cu(ClO4)2·6H2O (0.270 mmol; 100 mg). The 
resulting reaction mixture was stirred at 40 ºC for 4 hours. After filtration, 
the blue solution obtained was left unperturbed for the slow evaporation 
of the solvent. Blue single crystals of 2, suitable for X-ray diffraction 
measurements, were obtained with a yield of 79% (86 mg; based on 
Naphtpy). Elemental analyses calcd. for C52H42Cl4Cu2N6O12 (2−2H2O): 
C, 53.12; H, 3.26; N, 7.15. Found: C, 54.74; H, 3.53; N, 7.62. IR (KBr 
pellet): ?̅? = 1613, 1556, 1480, 1356, 1087, 793, 618 cm−1. 
Compound 3: 0.439 mmol (171 mg) of Naphtpy was dissolved in 50 mL 
of warm methanol at 40 ºC. 0.440 mmol (75 mg) of CuCl2·2H2O was 
dissolved in 10 mL of methanol at 40 ºC. The two solutions were cooled 
down to room temperature and subsequently mixed. The resulting light-
green solution was stirred at room temperature for 4 hours. After filtration, 
the solution was left unperturbed for the slow evaporation of the solvent. 
Blue single crystals of 3, suitable for X-ray diffraction measurements, 
were obtained with a yield of 63% (160 mg; based on Naphtpy). 
Elemental analyses calcd. for C52H38Cl4Cu2N6O2 (3−3MeOH−H2O): C, 
59.61; H, 3.66; N, 8.02. Found: C, 60.41; H, 3.81; N, 8.27. IR (KBr pellet): 
?̅? = 3417, 3057, 1604, 1570, 1478 cm−1. 
Compound 4: 0.385 mmol (103 mg) of Cltpy was dissolved in 15 mL of 
warm methanol at 40 ºC. This solution was subsequently added to a 
warm methanolic solution (10 mL) of CuCl2·2H2O (0.381 mmol; 65 mg). 
The resulting reaction mixture was stirred at 40 ºC for 4 hours. After 
filtration, the green solution was left unperturbed for the slow evaporation 
of the solvent. Light-green single crystals of 4, suitable for X-ray 
diffraction measurements, were obtained with a yield of 83% (127 mg; 
based on Cu). Elemental analyses calcd. for C15H10Cl3CuN3: C, 44.80; H, 
2.51; N, 10.45. Found: C, 44.80; H, 2.51; N, 10.45. IR (KBr pellet): ?̅? = 
3091, 3034, 1591, 1557, 1470, 1417, 1017, 791 cm−1. 
Compound 5: 0.374 mmol (100 mg) of Cltpy was dissolved in 15 mL of 
warm methanol at 40 ºC. This solution was added to a warm solution of 
Cu(ClO4)2·6H2O (0.351 mmol; 130 mg) in 10 mL of methanol. The 
resulting reaction mixture was stirred at 40 ºC for 4 hours. After filtration, 
the blue solution was left unperturbed for the slow evaporation of the 
solvent. 5 was obtained as a crystalline material with a yield of 42% (154 
mg, based on copper). Elemental analyses calcd. for C30H20Cl6CuN6O8, 
namely for [Cu(Cltpy)2](ClO4)2(H2O): C, 44.16; H, 2.72; N, 10.30. Found: 
C, 44.62; H, 2.56; N, 10.10. IR (KBr pellet): ?̅? = 3357, 3080, 1597, 1558, 
1476, 1247, 1086, 792, 622 cm−1. It can be stressed that the solid-state 
structures of [Cu(Cltpy)(ClO4)2(H2O)][40] and [Cu(Cltpy)2](ClO4)2[24] have 
been reported. 
X-ray diffraction 
Data for compounds 1, 2, 3 and 4 were obtained at 100 K on a Bruker 
APEX II CCD diffractometer at the Advanced Light Source beam-line 
11.3.1 at Lawrence Berkeley National Laboratory, from a silicon 111 
monochromator ( = 0.77490 Å), respectively on a blue plate of 
dimensions 0.19 × 0.04 × 0.02 mm3, a blue block of dimensions 0.04 × 
0.03 × 0.01 mm3, a blue-green block of dimensions 0.22 × 0.15 × 0.10 
mm3 and a blue-green block of dimensions 0.22 × 0.06 × 0.06 mm3. 
Crystals of 1 were found to be twinned. Twinning was found within APEX 
using RLATT,[41] and then analysed with CELL_NOW[42] that found the 
proper unit cell, twinning low and ascribed reflection to either or both 
components. Cell refinement and integration were then performed by 
SAINT[41] as a 2-component twin, keeping the cell of both components 
identical. TWINABS[42] was used for absorption corrections and produced 
HKLF4 and HKLF5 data, respectively for initial structure solution and final 
refinement. Data reduction and absorption corrections for compounds 2, 
3 and 4 were performed with SAINT and SADABS,[43] respectively. The 
structures were solved by intrinsic phasing with SHELXT.[44] All structures 
were refined by full-matrix least-squares on F2 with SHELXL.[45] 
All details can be found in CCDC 1983582−1983585 that contain the 
supplementary crystallographic data for this paper. These data can be 
obtained free of charge from The Cambridge Crystallographic Data 
Center via https://summary.ccdc.cam.ac.uk/structure-summary-form. It 
should be noted that the structure of a polymorph of compound 4 has 
been reported (CCDC entry 1021666).[17] 
Agarose Gel electrophoresis 
Stock solutions of the different complexes were prepared in 1 mM 
sodium cacodylate–20 mM NaCl buffer (pH = 7.2). pBR322 plasmid DNA 
aliquots (0.01 mg mL−1; 15 μM in base pairs) in 1 mM cacodylate–20 mM 
NaCl buffer were incubated with 1−4 for 1 h at 37 °C. For the studies with 
the presence of a reducing agent, ascorbic acid (1 mM cacodylate–20 
mM NaCl buffer) was subsequently added (in the case of the 
experiments without ascorbic acid, this step was not done), and the 
resulting mixture was incubated at 37 °C for an additional hour. Then, the 
reaction samples were quenched with 4 μL of a xylene cyanol 1X 
aqueous solution (containing 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue and 0.25% (w/v) xylene cyanol), and consequently 
electrophoretized in agarose gel (1% in TAE buffer) for 1 h at 1.5 V cm−1, 
using a Bio-Rad horizontal tank connected to a Consort EV231 variable 
potential power supply. Afterwards, the DNA was stained with SYBR® 
safe and the gel was photographed with a BIORAD Gel Doc™ EZ Imager. 
Samples of free DNA and DNA in the presence of ascorbic acid were 
used as controls. 
Fluorescence spectroscopy 
Stock solutions (1 mL) of 1−4 (5 mM) were prepared in milli-Q water. 
These stock solutions were freshly prepared (viz. just before use). The 
samples to be analysed were prepared by addition of aliquots of the 
complex stock solutions (in the concentration range 5–200 μM.) to the 
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cacodylate–20 mM NaCl buffer (pH = 7.2). A solution ct-DNA/EB (i.e., 
without complex) in cacodylate buffer was used as a blank. Fluorescence 
spectra were recorded at constant concentrations of EB and ct-DNA, 
namely 25 μM at room temperature, after 24 h incubation at 37 °C, on a 
Nandog™-Horiba Jobin Yvon spectrofluorometer with a 450 W xenon 
lamp using a computer for spectral subtraction and noise reduction. Each 
sample was scanned twice in a range of wavelengths between 500 and 
730 nm, after excitation at 520 nm. 
UV-Vis studies 
Stock solutions (1 mL) of 1−4 (5 mM) were prepared in milli-Q water, just 
before use. The samples to be analysed were prepared by the addition of 
increasing amounts of ct-DNA (from 0 to 25 μM, in base pairs) to a 25 μM 
solution of the complex tested. The UV-Vis spectra were recorded using 
a Varian Cary-100 spectrophotometer. 
Cytotoxicity studies 
Human ovarian carcinoma cell line A2780 (ECACC 93112519) and its 
derived cisplatin-resistant cell line A2780 cis (ECACC 93112517) were 
routinely maintained in RPMI 1640 medium (Gibco) supplemented with 
10% heat-inactivated Foetal Bovine Serum (FBS), GlutaMAX™ (Gibco) 
and 1% Antibiotic-Antimycotic solution (Gibco), in standard growth 
conditions (37 ºC and 5% CO2). Human cervix adenocarcinoma cell line 
HeLa (ATCC CCL-2™) was routinely maintained in MEM α medium 
without nucleosides (Gibco) supplemented with 10% heat-inactivated 
FBS, GlutaMAX™ (Gibco) and 1% Antibiotic-Antimycotic solution (Gibco), 
in standard growth conditions. All tested compounds were kept in DMSO 
stocks at 50 mM and stored at -20 ºC. All working concentrations were 
prepared in cell culture media with a maximum of 0.5 % of DMSO.  
Cells in exponential growth were plated in 96-well plates at a density of 3 
× 103 cells/well and were allowed to grow overnight. Next, the cells were 
treated with different concentrations of each compound, ranging from 100 
nM to 200 µM, during 24 h and 72 h of incubation, and 10 μL of 
PrestoBlue reagent (Invitrogen) were subsequently added following the 
standard protocol.[46] After 3 h of incubation, fluorescence was measured 
using a Victor3 multiwell microplate reader (excitation at 531 nm 
emission at 572 nm) (Perkin Elmer). The relative cell viability (%) for 
each sample related to the control cells without treatment was calculated. 
Each sample was tested in triplicates, in three independent experiments. 
In vitro apoptosis assay 
Induction of apoptosis in vitro by all compounds was determined by 
means of a flow cytometric assay with Annexin V-FITC by using an 
Annexin Annexin V-FITC Staining Kit (eBioscience, Thermo Scientific). 
HeLa cells in exponential growth were plated in 6-well plates at a density 
of 1 × 105 cells/well and were allowed to grow overnight. Subsequently, 
the cells were treated with each compound, using concentrations equal 
to their respective IC50 for 24 h (cisplatin was used as a reference, and 
untreated cells as a negative control). The cells were collected, washed 
with PBS, and resuspended in binding buffer (200 μL) and staining was 
accomplished by following the manufacturer's protocol. In brief, Annexin 
V–fluorescein isothiocyanate (FITC; 5 μL) and Propidium Iodide (10 μL) 
were added to the samples, which were then incubated 15 min at room 
temperature in the dark. The number of apoptotic cells was analysed by 
means of flow cytometry (FACSCalibur, Becton Dickinson). 
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